Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.

Stocks | Futures | Watchlist | More
or

Biolinerx Ltd (BLRX)

Biolinerx Ltd (BLRX)

[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]]
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 120,289
  • Shares Outstanding, K 39,055
  • Annual Sales, $ 0 K
  • Annual Income, $ -30,020 K
  • 60-Month Beta 2.04
  • Price/Sales N/A
  • Price/Cash Flow N/A
  • Price/Book 4.53
Trade BLRX with:

Analyst Rating / Earnings Estimates

Current Rating
See More
Strong Buy
Based on 2 analysts offering recommendations.
Earnings Estimates - Current Qtr 03/31/21
See More
  • Average Estimate -0.15
  • Number of Estimates 2
  • High Estimate -0.14
  • Low Estimate -0.16
  • Prior Year -0.60
  • Growth Rate Est. (year over year) +75.00%

Price Performance

See More
Period Period Low Period High Performance
1-Month
2.83 +2.47%
on 03/03/21
4.23 -31.44%
on 02/08/21
-0.20 (-6.45%)
since 02/03/21
3-Month
2.27 +27.75%
on 12/09/20
4.23 -31.44%
on 02/08/21
+0.59 (+25.54%)
since 12/03/20
52-Week
1.06 +173.35%
on 03/18/20
4.23 -31.44%
on 02/08/21
+1.02 (+54.26%)
since 03/03/20

Most Recent Stories

More News
BioLineRx Ltd. to Host Earnings Call

NEW YORK, NY / ACCESSWIRE / February 23, 2021 / BioLineRx Ltd. (NASDAQ:BLRX) will be discussing their earnings results in their 2020 Fourth Quarter Earnings call to be held on February 23, 2021 at 10:00...

BLRX : 2.90 (-5.84%)
BioLineRx Reports Year-End 2020 Financial Results and Provides Corporate Update

, /PRNewswire/ -- BioLineRx Ltd. (NASDAQ: BLRX) (TASE: BLRX), a late clinical-stage biopharmaceutical company focused on oncology, today reports its financial results for the year ended and provides...

BLRX : 2.90 (-5.84%)
BioLineRx to Report Annual 2020 Results on February 23, 2021

, /PRNewswire/ -- BioLineRx Ltd. (NASDAQ: BLRX) (TASE: BLRX), a late clinical-stage biopharmaceutical company focused on oncology, announced today it will release its audited financial results for the...

BLRX : 2.90 (-5.84%)
BioLineRx Announces Closing of $34.5 Million Bought Deal Offering and Full Exercise of the Option of the Underwriter

, /PRNewswire/ -- BioLineRx Ltd. (NASDAQ: BLRX) (TASE: BLRX), a late clinical-stage biopharmaceutical company focused on oncology, today announced the closing of its previously announced underwritten...

BLRX : 2.90 (-5.84%)
Aclaris (ACRS) Up on Preliminary Data for MK2 Inhibitor in RA

Aclaris (ACRS) posts favorable preliminary topline results from a phase IIa study evaluating its investigational oral candidate ATI-450 for treating moderate to severe rheumatoid arthritis. Shares up.

UTHR : 163.21 (-2.03%)
BLRX : 2.90 (-5.84%)
INFI : 2.90 (-5.84%)
ACRS : 21.98 (-5.46%)
BioLineRx Increases Previously Announced Bought Deal Offering to $30 Million

, /PRNewswire/ -- BioLineRx Ltd. (NASDAQ: BLRX) (TASE: BLRX), a late clinical-stage biopharmaceutical company focused on oncology, today announced that due to demand, the underwriter has agreed to increase...

BLRX : 2.90 (-5.84%)
BioLineRx Announces $10 Million Bought Deal Offering

, /PRNewswire/ -- BioLineRx Ltd. (NASDAQ: BLRX) (TASE: BLRX), a late clinical-stage biopharmaceutical company focused on oncology, today announced that it has entered into an underwriting agreement with...

BLRX : 2.90 (-5.84%)
RedHill's (RDHL) RHB-204 Gets FDA Fast Track Designation

RedHill (RDHL) gets Fast Track status from the FDA for the treatment of nontuberculous mycobacteria (NTM) disease.

UTHR : 163.21 (-2.03%)
BLRX : 2.90 (-5.84%)
RDHL : 7.76 (-0.51%)
SRRA : 14.81 (+0.34%)
Altimmune (ALT) Begins Phase II Study for Chronic Hepatitis B

Altimmune (ALT) enrolls the first patient in a phase II study evaluating HepTcell for the treatment of patients with chronic hepatitis B. Shares rise.

IRWD : 9.97 (+4.62%)
BLRX : 2.90 (-5.84%)
ALT : 14.37 (-8.82%)
SRRA : 14.81 (+0.34%)
Thinking about buying stock in Marathon Patent Group, Riot Blockchain, Twitter, BioLineRx, or Jaguar Health?

, /PRNewswire/ -- InvestorsObserver issues critical PriceWatch Alerts for MARA, RIOT, TWTR, BLRX, and JAGX.

BLRX : 2.90 (-5.84%)
JAGX : 1.88 (-9.62%)
MARA : 36.62 (+4.96%)
RIOT : 49.57 (+0.96%)
TWTR : 70.86 (-3.81%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 64% Buy with a Weakest short term outlook on maintaining the current direction.

Long term indicators fully support a continuation of the trend.

See More Share

Business Summary

Bioline RX Ltd. is a biopharmaceutical development company. BioLineRx is dedicated to building a portfolio of products for unmet medical needs or with advantages over currently available therapies. The Company's portfolio consists of clinical stage candidates including BL-1020 for schizophrenia , BL-1040,...

See More

Key Turning Points

3rd Resistance Point 3.39
2nd Resistance Point 3.31
1st Resistance Point 3.20
Last Price 2.90
1st Support Level 3.01
2nd Support Level 2.93
3rd Support Level 2.82

See More

52-Week High 4.23
Fibonacci 61.8% 3.02
Last Price 2.90
Fibonacci 50% 2.65
Fibonacci 38.2% 2.27
52-Week Low 1.06

See More

Want to use this as
your default charts setting?
Learn about our Custom Templates
Switch the Market flag
above for targeted data.
Open the menu and switch the
Market flag for targeted data.
Get Streaming Chart Updates
Switch your Site Preferences
to Interactive Chart
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.

Free Barchart Webinar